Takeda Pharma USA Inc v. Sun Pharmaceutical Industries Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Takeda Pharmaceuticals U.S.A., Inc. (Delaware)
  • Defendant: Sun Pharmaceutical Industries Ltd. (India)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: Takeda Pharmaceuticals U.S.A., Inc. v. Sun Pharmaceutical Industries Ltd., 1:26-cv-08064, D.N.J., 07/01/2026
• Venue Allegations: Venue is alleged based on Defendant's business activities, including the anticipated sale and distribution of the accused generic drug product throughout the United States and specifically within New Jersey. The complaint also notes Defendant's history of availing itself of the New Jersey courts in prior patent litigation.
• Core Dispute: Plaintiff alleges that Defendant's filing of an Abbreviated New Drug Application (ANDA) to market a generic version of the cancer drug ICLUSIG® (ponatinib) constitutes an act of infringement of four U.S. patents covering specific crystalline forms of the active pharmaceutical ingredient.
• Technical Context: The technology relates to pharmaceutical polymorphism, specifically the identification and characterization of stable, crystalline forms of ponatinib hydrochloride, a tyrosine-kinase inhibitor used for treating certain types of leukemia.
• Key Procedural History: The complaint notes that the patents-in-suit are listed in the FDA's "Orange Book" with respect to ICLUSIG®. It also references prior patent litigation involving Takeda and other generic manufacturers, as well as prior litigation in the district involving Sun, to support jurisdiction and venue.

Case Timeline

Date	Event
2012-12-12	Earliest Priority Date for '470, '895, '897, and '086 Patents
2016-11-15	U.S. Patent No. 9,493,470 Issues
2021-12-07	U.S. Patent No. 11,192,895 Issues
2021-12-07	U.S. Patent No. 11,192,897 Issues
2022-07-12	U.S. Patent No. 11,384,086 Issues
2026-05-21	Date of Defendant's Paragraph IV Notice Letter
2026-07-01	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,493,470

• Patent Identification: U.S. Patent No. 9,493,470, "Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt," issued November 15, 2016.

The Invention Explained

• Problem Addressed: The development of pharmaceutical drugs requires an understanding of the potential polymorphic forms of an active pharmaceutical ingredient (API) U.S. Patent 9493470, col. 3:13-21 Inconsistent manufacturing or unknown stability of different crystal forms can lead to variable drug performance and issues with drug development U.S. Patent 9,493,470, col. 3:13-27
• The Patented Solution: The patent discloses and characterizes novel crystalline forms (polymorphs and pseudopolymorphs) of ponatinib hydrochloride, the API in the drug ICLUSIG® '470 Patent, abstract The invention provides specific, identifiable, and reproducible solid-state forms of the API, which are defined by physical characteristics such as X-ray powder diffraction (XRPD) patterns, as shown for "Form A" in Figure 3 of the patent '470 Patent, FIG. 3 '470 Patent, col. 4:55-68
• Technical Importance: Identifying and claiming specific, stable crystalline forms of an API is critical for ensuring consistent manufacturing, bioavailability, and stability of a pharmaceutical product.

Key Claims at a Glance

• The complaint alleges infringement of "one or more claims" but does not specify which claims will be asserted Compl. ¶32 Independent claim 1 is representative.
• Independent Claim 1 requires:
  • A crystalline form of ponatinib hydrochloride,
  • characterized by an x-ray powder diffraction pattern comprising 2θ values (±0.3) at 5.9, 7.1, 12.5, 19.3, 23.8, and 26.1.

U.S. Patent No. 11,192,895

• Patent Identification: U.S. Patent No. 11,192,895, "Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt," issued December 7, 2021.

The Invention Explained

• Problem Addressed: As with the '470 patent, this patent addresses the need for well-defined and stable solid forms of the ponatinib hydrochloride API for reliable pharmaceutical development '895 Patent, col. 3:9-27
• The Patented Solution: The patent claims methods of treating specific cancers by administering a composition containing one of several specifically identified crystalline forms of ponatinib hydrochloride '895 Patent, col. 3:20-36 The patent identifies and extensively characterizes multiple distinct polymorphic forms, designated as Forms A through K, providing detailed analytical data for each '895 Patent, col. 4:40-54 '895 Patent, FIG. 1
• Technical Importance: Claiming a method of treatment using a specific, characterized API polymorph can extend patent protection for a drug product by covering the approved therapeutic use of that particular solid-state form.

Key Claims at a Glance

• The complaint alleges infringement of "one or more claims" but does not specify which claims will be asserted Compl. ¶41 Independent claim 1 is representative of the method of treatment claims.
• Independent Claim 1 requires:
  • A method for treating chronic phase chronic myeloid leukemia in a subject in need thereof
  • comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one crystalline form of ponatinib hydrochloride
  • characterized by one of ten different sets of X-ray powder diffraction patterns corresponding to Forms A, B, C, D, E, F, G, H, I, or J.

Multi-Patent Capsule: U.S. Patent No. 11,192,897

• Patent Identification: U.S. Patent No. 11,192,897, "Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt," issued December 7, 2021.
• Technology Synopsis: The patent, part of the same family as the other patents-in-suit, discloses and claims specific crystalline forms of ponatinib and its hydrochloride salt '897 Patent, abstract It particularly focuses on "Form A" of ponatinib hydrochloride, providing a method for its preparation and defining its characteristics '897 Patent, col. 16:9-25
• Asserted Claims: The complaint alleges infringement of "one or more claims" Compl. ¶50 Independent claim 1 claims "A crystalline Form A of ponatinib hydrochloride."
• Accused Features: The accused feature is the crystalline form of ponatinib hydrochloride contained within Sun's ANDA Product, which is alleged to be the claimed Form A '897 Patent, claim 1 Compl. ¶52

Multi-Patent Capsule: U.S. Patent No. 11,384,086

• Patent Identification: U.S. Patent No. 11,384,086, "Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt," issued July 12, 2022.
• Technology Synopsis: This patent also discloses and claims crystalline forms of ponatinib hydrochloride '086 Patent, abstract The claims are directed to the specific physical characteristics of these forms, particularly Form A, as identified by X-ray powder diffraction data '086 Patent, claim 1
• Asserted Claims: The complaint alleges infringement of "one or more claims" Compl. ¶59 Independent claim 1 claims a crystalline form of ponatinib hydrochloride characterized by an XRPD pattern with at least three peaks from a specified list.
• Accused Features: The accused feature is the crystalline form of ponatinib hydrochloride in Sun's ANDA product, which is alleged to possess the characteristic XRPD pattern of the claimed polymorph '086 Patent, claim 1 Compl. ¶61

III. The Accused Instrumentality

• Product Identification: The accused instrumentality is "Sun's ANDA Product," identified as ponatinib hydrochloride tablets in 10 mg, 15 mg, 30 mg, and 45 mg strengths, for which Defendant Sun submitted ANDA No. 218126 to the FDA Compl. ¶26
• Functionality and Market Context: The complaint alleges that Sun's ANDA Product is a generic version of Plaintiff's ICLUSIG® (ponatinib) drug product Compl. ¶30 ICLUSIG® is indicated for the treatment of adult patients with acute lymphoblastic leukemia and chronic myeloid leukemia Compl. ¶8 The complaint alleges that upon FDA approval, Sun intends to manufacture, market, and sell its generic product in the United States before the expiration of the patents-in-suit Compl. ¶27

IV. Analysis of Infringement Allegations

The complaint does not provide specific, element-by-element infringement allegations or reference any claim chart exhibits. The infringement theory must be inferred from the general allegations. Therefore, a formal claim chart table cannot be constructed. The narrative infringement theories are summarized below.

• Infringement Theory for '470 Patent (Composition of Matter Claims): The complaint alleges that Sun's submission of ANDA No. 218126, which seeks approval to manufacture and sell "Sun's ANDA Product," constitutes infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶32 The infringement theory is that the ponatinib hydrochloride API in Sun's ANDA Product is, or is contained within, a crystalline form that meets the limitations of the asserted claims of the '470 patent, such as the XRPD peak locations defining "Form A."
• Infringement Theory for '895 Patent (Method of Treatment Claims): The complaint alleges that upon approval, Sun will induce infringement under 35 U.S.C. § 271(b) by marketing its ANDA product Compl. ¶44 The infringement theory is that the product's FDA-approved labeling will instruct and encourage physicians and patients to administer the generic drug for the treatment of chronic myeloid leukemia, thereby directing them to perform the steps of the asserted method claims Compl. ¶11 Compl. ¶44
• Identified Points of Contention:
  • Technical Question (for Composition Claims): The central issue for the composition claims will be one of identity. The complaint does not provide any technical data (e.g., XRPD patterns) from Sun's ANDA. A primary question for the court will be whether the specific crystalline form of ponatinib hydrochloride in Sun's ANDA product exhibits the physical characteristics, such as the specific 2θ peaks, required by claims like Claim 1 of the '470 patent.
  • Legal/Factual Question (for Method Claims): For the method of treatment claims, the key issue will be inducement. The complaint alleges that the labeling for ICLUSIG® encourages the claimed methods Compl. ¶11 This raises the question of whether the label for Sun's generic product, which must be substantially similar, will be found to contain instructions that actively encourage or direct physicians to perform the patented methods of treatment, thereby establishing the requisite intent for induced infringement.

No probative visual evidence provided in complaint.

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail to identify specific claim term disputes. However, based on the nature of the patents, the following term will be central to the dispute.

• The Term: "a crystalline form ... characterized by an x-ray powder diffraction pattern comprising 2θ values (±0.3) at [list of peaks]" (from '470 Patent, claim 1).
• Context and Importance: This term is the entire basis for defining the patented crystalline form. Practitioners may focus on this term because the infringement analysis will hinge entirely on whether the XRPD pattern of Sun's ANDA product can be read to meet this definition. The dispute will likely involve expert testimony on the proper interpretation of XRPD data, including instrument calibration, peak selection, and the significance of relative peak intensities.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The claims explicitly include a margin of error (±0.3) for the 2θ values, which may support an argument that the definition is not rigidly fixed and can encompass patterns with slight variations '470 Patent, claim 1 The specification may also describe the claimed form as being "substantially" as shown in a figure, which could be argued to allow for some deviation from the exemplary data '470 Patent, col. 4:63-65
  • Evidence for a Narrower Interpretation: The patent provides highly specific examples, including XRPD patterns with precise peak locations and relative intensities for specific batches of the API '895 Patent, FIG. 3 '895 Patent, FIG. 4 A party may argue that the claims should be construed as limited to crystalline forms that closely match these specific, disclosed embodiments, and that forms with different relative intensities or additional peaks fall outside the claim scope.

VI. Other Allegations

• Indirect Infringement: The complaint alleges induced infringement based on the contention that the FDA-approved labeling for Sun's ANDA Product will instruct physicians and patients to administer the drug for its approved indications, which are alleged to be covered by the method claims of the patents-in-suit Compl. ¶11 Compl. ¶35 Compl. ¶44 Contributory infringement is alleged on the basis that Sun's product is especially adapted for an infringing use and has no substantial non-infringing use Compl. ¶36 Compl. ¶45
• Willful Infringement: Willfulness is not explicitly pleaded, but the complaint alleges that Sun has had knowledge of the patents-in-suit since "at least the date of Sun's ANDA submission" as a result of its Paragraph IV certification Compl. ¶37 Compl. ¶46 Compl. ¶55 Compl. ¶64 The complaint also asserts that the case is "exceptional" and seeks attorneys' fees under 35 U.S.C. § 285 Compl. ¶39 Compl. ¶48 Compl. ¶57 Compl. ¶66

VII. Analyst's Conclusion: Key Questions for the Case

• A central question will be one of evidentiary proof: What will discovery reveal about the physical characteristics of the ponatinib hydrochloride in Sun's ANDA product, and will its XRPD pattern and other properties fall within the scope of the asserted claims defining specific crystalline forms, such as Form A?
• A second core issue will be one of inducement: Assuming the method of treatment claims are valid, will the language in the FDA-approved label for Sun's generic product be found to constitute active encouragement to perform the patented methods, thus satisfying the legal standard for induced infringement?
• A key technical dispute will likely revolve around claim construction and measurement variability: How will the court define the boundaries of the claimed polymorphs, and can any differences between the XRPD pattern of Sun's product and the patent's examples be attributed to normal experimental variation, or do they signify a different, non-infringing crystalline form?